TORONTO – Psyence Group Inc., a leading platform in naturally derived psychedelic therapy and the development and commercialization of related technologies and products reported it has launched its functional mushroom brand, “GOODMIND”, through a South African-based special purpose vehicle called Goodmind Ltd.
The SPV will be responsible for the production, commercialization and sale of GOODMIND functional mushroom products, which will in future include additional psilocybin containing products, subject to compliance with all applicable local laws and regulations in the jurisdictions in which the SPV operates. The primary aim of the SPV is to establish a revenue-generating business by executing on opportunities in the functional mushroom space.
Goodleaf is the leading cannabis brand in South Africa with established distribution lines through retail stores, online, wholesale, and deli and coffee shops.
Goodleaf and Psyence have strong and established track records in the cannabis industry in Southern Africa. Goodleaf has demonstrated great competence in launching new consumer goods in a young industry. Psyence is experienced in procurement, manufacturing and logistics. Both companies intend to leverage their knowledge and experience in the functional mushroom space.
Jody Aufrichtig, Co-Founder, President, and CEO, Psyence Group Inc. says: “We are delighted to partner with the leading Cannabis brand in Africa, Goodleaf, who have a proven track record of successfully launching and distributing high-quality retail and online products. Goodleaf’s extensive distribution outlets will ensure that our functional mushroom products can quickly penetrate the growing market.”
Warren Schewits, CEO & Founder of Goodleaf added: “Our experience in developing and launching new consumer products will be invaluable as we make headway in the functional mushroom space. There is no doubt that there is a growing demand for wellness products and we are extremely excited to collaborate with Psyence as we launch GOODMIND and also bring a range of functional mushroom products to market.”
The Psyence Group sets the global standard for natural psychedelics. The executive team have international experience in the business of science and medicine and include global experts in palliative care, neurology, neuroscience and drug development. Psyence has built and operates one of the first federally licensed commercial psilocybin cultivation and production facilities. Psyence is pioneering the use of natural psilocybin for the long-term treatment of psychological trauma and its mental health consequences.
We seek Safe Harbor.
